Home › Autoimmune Diseases › Florida › St. Petersburg
Autoimmune Diseases clinical trials in St. Petersburg, FL
3 studies for Autoimmune Diseases are looking for participants at sites in and around St. Petersburg (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecruitingPhase 2/3
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients, St. Petersburg
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
RecruitingPhase 3
- University of Southern Florida, St. Petersburg
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- All Children's Hospital, St. Petersburg
About Autoimmune Diseases
Autoimmune diseases are where your immune system attacks healthy cells in your body by mistake. Learn about the symptoms, tests, and treatments.
More about Autoimmune Diseases on MedlinePlus
Autoimmune Diseases trials in other cities
- Houston, TX21 studies
- Washington, DC19 studies
- New York City, NY19 studies
- Philadelphia, PA16 studies
- Durham, NC15 studies
- Boston, MA13 studies
- Chicago, IL12 studies
- Los Angeles, CA12 studies
- Dallas, TX9 studies
- Atlanta, GA8 studies
- Portland, OR8 studies
- Milwaukee, WI8 studies
Other studies in St. Petersburg
- Non-Small Cell Lung Cancer21 studies
- Breast Cancer11 studies
- Obesity9 studies
- Overweight9 studies
- Colorectal Cancer8 studies
- Heart Failure8 studies
- Lung Cancer7 studies
- Endometrial Cancer6 studies
- Burkitt Lymphoma6 studies
- Ovarian Cancer6 studies
- Type 2 Diabetes5 studies
- COPD5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.